Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing Phase 3 trial.
The tetravalent vaccine, which was found to be well tolerated, met its primary efficacy endpoint in a pivotal Phase 3 trial.
“We are very encouraged by the performance of our dengue vaccine candidate in the study. This brings us one step closer to helping the world tackle the massive burden of dengue,” said Dr Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda.
